Literature DB >> 25592059

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

Tamara Alpermann1, Claudia Haferlach1, Christiane Eder1, Niroshan Nadarajah1, Manja Meggendorfer1, Wolfgang Kern1, Torsten Haferlach1, Susanne Schnittger2.   

Abstract

Trisomy 8 is the most frequent cytogenetically gained aberration in AML. We compared 79 adult de novo AML with trisomy 8 as the sole cytogenetic abnormality (+8sole) to 511 normal karyotype AML patients (NK). +8sole patients were older (p=0.013), presented lower WBC counts (p=0.010), harbored more often ASXL1 mutations (p<0.001) and RUNX1 mutations (p=0.009), but less frequent FLT3-ITD (p=0.038), NPM1 mutations (p<0.001) and double-mutated CEBPA (p=0.038) than NK patients. No prognostic difference was found between +8sole and NK. With respect to genetic stability we found +8sole was instable, and molecular markers were either stable or gained in number and diversity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; Genetic stability; Molecular mutations; Prognosis; Trisomy 8

Mesh:

Substances:

Year:  2014        PMID: 25592059     DOI: 10.1016/j.leukres.2014.11.026

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.

Authors:  Aliaa Arina Rosli; Adam Azlan; Yaashini Rajasegaran; Yee Yik Mot; Olaf Heidenreich; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Clin Exp Med       Date:  2022-10-13       Impact factor: 5.057

Review 2.  Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.

Authors:  Michael Medinger; Claudia Lengerke; Jakob Passweg
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

3.  Formaldehyde, Hematotoxicity, and Chromosomal Changes-Response.

Authors:  Nathaniel Rothman; Luoping Zhang; Martyn T Smith; Roel Vermeulen; Qing Lan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-01       Impact factor: 4.090

Review 4.  Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.

Authors:  Hubert Hackl; Ksenia Astanina; Rotraud Wieser
Journal:  J Hematol Oncol       Date:  2017-02-20       Impact factor: 17.388

5.  CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.

Authors:  Zhi-Jie Wu; Xin Zhao; Lauren G Banaszak; Fernanda Gutierrez-Rodrigues; Keyvan Keyvanfar; Shou-Guo Gao; Diego Quinones Raffo; Sachiko Kajigaya; Neal S Young
Journal:  Int J Oncol       Date:  2018-02-28       Impact factor: 5.650

6.  A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain.

Authors:  Filomena Nozza; Gabriella Vona; Stefania Trino; Fiorella D'Auria; Francesco La Rocca; Vitina Grieco; Luciana Possidente; Luciana De Luca; Pellegrino Musto
Journal:  Mol Cytogenet       Date:  2019-07-05       Impact factor: 2.009

Review 7.  Acute Myeloid Leukemia: A Concise Review.

Authors:  Jennifer N Saultz; Ramiro Garzon
Journal:  J Clin Med       Date:  2016-03-05       Impact factor: 4.241

8.  Prognostic Significance of Mixed-Lineage Leukemia (MLL) Gene Detected by Real-Time Fluorescence Quantitative PCR Assay in Acute Myeloid Leukemia.

Authors:  Sai Huang; Hua Yang; Yan Li; Cong Feng; Li Gao; Guo-Feng Chen; Hong-Hao Gao; Zhi Huang; Yong-Hui Li; Li Yu
Journal:  Med Sci Monit       Date:  2016-08-26

9.  The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.

Authors:  T Haferlach; A Stengel; S Eckstein; K Perglerová; T Alpermann; W Kern; C Haferlach; M Meggendorfer
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

10.  Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Authors:  Giorgia Simonetti; Antonella Padella; Italo Farìa do Valle; Maria Chiara Fontana; Eugenio Fonzi; Samantha Bruno; Carmen Baldazzi; Viviana Guadagnuolo; Marco Manfrini; Anna Ferrari; Stefania Paolini; Cristina Papayannidis; Giovanni Marconi; Eugenia Franchini; Elisa Zuffa; Maria Antonella Laginestra; Federica Zanotti; Annalisa Astolfi; Ilaria Iacobucci; Simona Bernardi; Marco Sazzini; Elisa Ficarra; Jesus Maria Hernandez; Peter Vandenberghe; Jan Cools; Lars Bullinger; Emanuela Ottaviani; Nicoletta Testoni; Michele Cavo; Torsten Haferlach; Gastone Castellani; Daniel Remondini; Giovanni Martinelli
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.